• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性结直肠癌中错配修复状态的个体内肿瘤异质性。

Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.

机构信息

Departments of General Surgery.

Department of General Surgery, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China.

出版信息

Appl Immunohistochem Mol Morphol. 2023 Feb 1;31(2):84-93. doi: 10.1097/PAI.0000000000001089. Epub 2022 Nov 22.

DOI:10.1097/PAI.0000000000001089
PMID:36409630
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9928560/
Abstract

Heterogeneous mismatch repair (MMR) status in metastatic colorectal cancer (mCRC) may associate with refractoriness to immunotherapy. We aimed here to study the concordance in MMR status between primary and paired metastasis in mCRC. Our study included 84 patients diagnosed with mCRC with primary and matched metastatic cancers. Immunohistochemistry was used to determine the MMR status of primary lesions and matched metastases. Pooled analysis of 913 cases was used to evaluate the prevalence and organ specificity of MMR status heterogeneity. The correlations between MMR pattern heterogeneity and clinical outcomes were analyzed. MMR status heterogeneity between primary and corresponding metastatic sites was exhibited by 10 (11.9%) patients. The prevalence of the heterogeneous MMR phenotype was significantly higher in primary tumors with deficient MMR (dMMR) than with proficient MMR (pMMR), which was verified in the pooled analysis ( P <0.001). Among patients with a dMMR primary tumor, the discrepancy was detected in liver, lung, ovary, peritoneum, and distant lymph node metastases. However, the discrepancy was confined to liver (26/440) or peritoneum (7/112) ( P =0.02) in patients with a pMMR primary tumor. Patients with or without MMR status heterogeneity experienced comparable overall survival ( P =0.452). Heterogeneous MMR patterns generally existed in a subset of patients with mCRC, particularly those with dMMR primary tumors. Testing the metastatic site may be valuable because the discordance of MMR status may potentially affect immune surveillance and immunotherapy.

摘要

转移性结直肠癌(mCRC)中异质性错配修复(MMR)状态可能与免疫治疗的耐药性有关。我们旨在研究 mCRC 原发灶和配对转移灶中 MMR 状态的一致性。本研究纳入了 84 例 mCRC 患者,其具有原发灶和匹配的转移性癌症。免疫组织化学用于确定原发灶和匹配转移灶的 MMR 状态。对 913 例病例的汇总分析用于评估 MMR 状态异质性的发生率和器官特异性。分析了 MMR 模式异质性与临床结局之间的相关性。10 例(11.9%)患者的原发灶和相应转移灶之间表现出 MMR 状态异质性。在 MMR 缺陷(dMMR)的原发肿瘤中,异质性 MMR 表型的发生率明显高于 MMR 功能良好(pMMR)的原发肿瘤,这在汇总分析中得到了验证(P<0.001)。在 dMMR 原发肿瘤患者中,在肝、肺、卵巢、腹膜和远处淋巴结转移中检测到差异。然而,在 pMMR 原发肿瘤患者中,差异仅限于肝(26/440)或腹膜(7/112)(P=0.02)。有无 MMR 状态异质性的患者的总生存情况相当(P=0.452)。异质性 MMR 模式通常存在于 mCRC 的一部分患者中,特别是那些具有 dMMR 原发肿瘤的患者。检测转移灶可能是有价值的,因为 MMR 状态的不一致可能会潜在地影响免疫监测和免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/be895eda91f6/pai-31-84-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/705198ca444a/pai-31-84-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/205b75e072dd/pai-31-84-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/f21d16157fa6/pai-31-84-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/e8e68130c340/pai-31-84-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/be895eda91f6/pai-31-84-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/705198ca444a/pai-31-84-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/205b75e072dd/pai-31-84-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/f21d16157fa6/pai-31-84-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/e8e68130c340/pai-31-84-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ad/9928560/be895eda91f6/pai-31-84-g005.jpg

相似文献

1
Intraindividual Tumor Heterogeneity of Mismatch Repair Status in Metastatic Colorectal Cancer.转移性结直肠癌中错配修复状态的个体内肿瘤异质性。
Appl Immunohistochem Mol Morphol. 2023 Feb 1;31(2):84-93. doi: 10.1097/PAI.0000000000001089. Epub 2022 Nov 22.
2
Comparison of Mismatch Repair Status Between Primary and Matched Metastatic Sites in Patients With Colorectal Cancer.比较结直肠癌患者原发灶与配对转移灶错配修复状态的差异。
J Natl Compr Canc Netw. 2019 Oct 1;17(10):1174-1183. doi: 10.6004/jnccn.2019.7308.
3
Mismatch Repair Status Correlates with Survival in Young Adults with Metastatic Colorectal Cancer.错配修复状态与转移性结直肠癌青年患者的生存相关。
J Surg Res. 2021 Oct;266:104-112. doi: 10.1016/j.jss.2021.03.040. Epub 2021 May 11.
4
Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort.全国性队列研究中,接受转移灶根治性局部治疗的错配修复缺陷型与 proficient Mismatch Repair 型转移性结直肠癌患者的生存情况。
Ann Surg Oncol. 2023 Oct;30(11):6762-6770. doi: 10.1245/s10434-023-13974-7. Epub 2023 Aug 1.
5
Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.原发肿瘤与转移灶之间错配修复状态和微卫星不稳定性的异质性及其对结直肠癌免疫治疗的影响。
Int J Mol Sci. 2022 Apr 17;23(8):4427. doi: 10.3390/ijms23084427.
6
Synchronous and metachronous primary colorectal cancers with concordant and discordant mismatch repair status.同步和异时性原发结直肠肿瘤伴一致和不一致的错配修复状态。
Hum Pathol. 2023 Nov;141:54-63. doi: 10.1016/j.humpath.2023.09.003. Epub 2023 Sep 23.
7
Prognostic value of Lynch syndrome, BRAF , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.Lynch 综合征、BRAF 和 RAS 突变状态对荷兰和法国队列汇总分析中错配修复缺陷/微卫星高度不稳定转移性结直肠癌的预后价值。
Cancer Med. 2023 Aug;12(15):15841-15853. doi: 10.1002/cam4.6223. Epub 2023 Jun 16.
8
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.转移性结直肠癌患者的错配修复状态和BRAF突变状态:CAIRO、CAIRO2、COIN和FOCUS研究的汇总分析
Clin Cancer Res. 2014 Oct 15;20(20):5322-30. doi: 10.1158/1078-0432.CCR-14-0332. Epub 2014 Aug 19.
9
Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.DNA 错配修复缺陷型转移性结直肠癌的化疗反应和预后。
Clin Colorectal Cancer. 2017 Sep;16(3):228-239. doi: 10.1016/j.clcc.2016.11.001. Epub 2016 Nov 26.
10
Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study.原发结直肠肿瘤与转移瘤之间错配修复状态的回顾性一致性研究。
Biosci Rep. 2019 Dec 20;39(12). doi: 10.1042/BSR20190730.

引用本文的文献

1
Pyrithione zinc alters mismatch repair to trigger tumor immunogenicity.吡硫翁锌改变错配修复以触发肿瘤免疫原性。
Oncogene. 2025 Apr;44(14):983-995. doi: 10.1038/s41388-024-03272-1. Epub 2025 Jan 15.
2
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.结直肠癌中 DNA 修复依赖性免疫原性缺陷:错误带来的机会。
Br J Cancer. 2024 Nov;131(10):1576-1590. doi: 10.1038/s41416-024-02848-8. Epub 2024 Sep 13.
3
DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.
DNA错配修复系统通过DNA甲基转移酶调节宫颈癌中PD-L1的表达。
Cancer Cell Int. 2024 Jan 10;24(1):25. doi: 10.1186/s12935-024-03214-7.
4
Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).结直肠癌的分子亚型分型:通向个性化治疗的桥梁(综述)
Oncol Lett. 2023 Apr 18;25(6):230. doi: 10.3892/ol.2023.13816. eCollection 2023 Jun.